Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Abuckatatime who wrote (10)	3/4/1998 7:02:00 AM
From: Arthur Radley	Respond to of 626

Morning Greg, Yes! Spheramine is still in preclinicals but it is my understanding that the monkey models are good indicators for efficacy in humans. In the December 1997 edition of Cell Transplantation, TTNP's technology was published, showing human neural cells were transplanted into the brains of rats. The technology greatly enhanced survival of the transplanted human cells, without any need for immune suppression. As you can see, they are in the earliest of stages with SPHERMINE, but if it works, the market is huge for such a drug.